Simulations Plus Inc 2026年季度报告

FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period endedNovember 30, 2025 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______to ______ Commission file number:001-32046 Simulations Plus, Inc.(Name of registrant as specified in its charter) 95-4595609 California (State or other jurisdiction of Incorporation or Organization)(I.R.S. Employer Identification No.) 800 Park Offices Drive, Suite 401Research Triangle Park, NC 27709(Address of principal executive offices including zip code) (661) 723-7723(Registrant’s telephone number, including area code) SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: Title of Each ClassCommon Stock, par value $0.001 per shareTrading SymbolSLPName of Each Exchange on Which RegisteredNASDAQ Stock Market LLC Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one): Large accelerated FilerNon-accelerated FilerEmerging Growth Company Accelerated FilerSmaller reporting company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of December31, 2025, was20,146,585. Simulations Plus, Inc.FORM 10-QFor the Quarterly Period Ended November30, 2025Table of ContentsPART I. FINANCIAL INFORMATIONPageItem 1.Condensed Consolidated Financial StatementsUnaudited Condensed Consolidated Balance Sheets at November 30, 2025 and August 31, 20253Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income for the three monthsended November 30, 2025 andNovember 30, 20244Unaudited Condensed Consolidated Statements of Shareholders’ Equity for the three months endedNovember 30,2025 andNovember 30, 20245Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended November 30, 2025and November 30, 20246Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures about Market Risk31Item 4.Controls and Procedures31PART II. OTHER INFORMATIONItem 1.Legal Proceedings31Item 1A.Risk Factors32Item 2.Unregistered Sales of Equity Securities and Use of Proceeds32Item 3.Defaults upon Senior Securities32Item 4.Mine Safety Disclosures32Item 5.Other Information32Item 6.Exhibits33Signatures34PART I. FINANCIAL INFORMATION SIMULATIONS PLUS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME(Unaudited) SIMULATIONS PLUS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) Simulations Plus, Inc.Notes to Condensed Consolidated Financial StatementsFor the three months ended November30, 2025 and November30, 2024 NOTE 1 – DESCRIPTION OF BUSINESS Simulations Plus, Inc. (the "Company", "we", "our") was incorporated in California on July 17, 1996. The Company is a global leaderand premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery anddevelopment, clinical trial operations, and commercialization. The Company supports its clients across the drug development lifecyclefrom the early discovery through all phases of clinical research and development (“R&D”), including clinical operations, to productcommercialization. The Company serves clients as a strategic partner throughout the entire drug development lifecycle, offeringsolutions that integrate scientific software platforms, artificial intelligence-augmented insights, and expert consulting. This optimizesefficiency, costs, and time-to-market for our clients and enhances